ICS-formoterol reliever versus ICS and short-acting β(2)-agonist reliever in asthma: a systematic review and meta-analysis

BACKGROUND: The Global Initiative for Asthma recommends as-needed inhaled corticosteroid (ICS)-formoterol as an alternative to maintenance ICS plus short-acting β(2)-agonist (SABA) reliever at step 2 of its stepwise treatment algorithm. Our aim was to assess the efficacy and safety of these two trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatter, Lee, Bruce, Pepa, Braithwaite, Irene, Holliday, Mark, Fingleton, James, Weatherall, Mark, Beasley, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836558/
https://www.ncbi.nlm.nih.gov/pubmed/33532465
http://dx.doi.org/10.1183/23120541.00701-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836558/
https://www.ncbi.nlm.nih.gov/pubmed/33532465
http://dx.doi.org/10.1183/23120541.00701-2020

Ejemplares similares